Rafael Pharmaceutical’s first-in-class clinical lead compound, CPI-613 ® (devimistat), targets enzymes that are involved in cancer cell energy metabolism and are located in the mitochondria of cancer cells. The pharmaceutical holdings comprise majority interests in Rafael Pharmaceuticals, Inc., and Lipomedix Pharmaceuticals Ltd. Rafael Holdings Inc. Rafael Holdings, Inc. owns interest in commercial real estate assets and clinical stage pharmaceutical companies. Dr. Sol J. Barer, Chairman of the Board of Teva Pharmaceuticals, Chairman of Centrexion Therapeutics, Lead Director of Contrafect Corp, Chairman of Neximmune, and Board member of 3DBiotherapeutics and Cerecor, Founding Chair of the Hackensack Meridian Center for Discovery and Innovation and advisor to the Israel Biotech Fund. Rafael’s lead AMD compound, CPI-613 ® (devimistat), is being evaluated in 19 ongoing or completed Phase I, I/II, II and III clinical studies as a single agent, as well as in combination with standard drug therapies, in patients diagnosed with advanced solid tumors or blood cancers.. Rafael Pharmaceuticals' lead compound, CPI-613 ® (devimistat), is a highly selective, well-tolerated and effective anti-cancer agent that is being evaluated in ongoing and completed Phase 1, 2 and 3 clinical trials. All Rafael Holdings properties are unencumbered by debt. 2021 January 19, 2021 Rafael Pharmaceuticals to Present at B. Riley Securities Virtual Oncology Investor Conference Learn More January 13, 2021 Rafael Pharmaceuticals to Present at 39th Annual J.P. Morgan Healthcare Conference Rafael Holdings is focused on development of novel cancer therapies. Howard S. Jonas has served as Chairman of the Board of Directors of the Company since August 17, 2017 and Chief Executive Officer since March 8, 2018. Rafael Pharmaceuticals to Present at B. Riley Securities Virtual Oncology Investor Conference. Rafael Holdings’ real estate provides exposure to Newark, NJ’s fast-reviving commercial market and features a 20-story office building and adjacent garage – on a developable site. Rafael Holdings Enhances Senior Management Team with Additions of Ameet Mallik, CEO and William Conkling, CCO Leadership Team Will Build on Pharma … Rafael Pharma will utilize the investment to further advance the clinical development of devimistat (CPI-613®) NEWARK, N.J., Jan. 23, 2019 /PRNewswire/ -- Rafael Holdings, Inc. (NYSE American: RFL) today announced that it has purchased a majority stake in Rafael Pharmaceuticals, Inc., (Rafael Pharma).Rafael Pharma is a clinical stage, metabolic oncology-therapeutics company … Mr. Jonas has been a director of Rafael Pharmaceuticals since April 2013 and was appointed Chairman of the Board in April 2016. It operates through the Real Estate and Pharmaceuticals … Please visit clinicaltrials.gov to learn more about clinical trials of CPI-613 ®.
How To Send Multiple Pictures On Galaxy S8, Ladd Drummond Ranch Size, Singapore Marine Industry Outlook 2020, Shipping From China To Us Time, Taj Gift Card Reload, How To Pronounce Barefoot, 2322 86th Street Brooklyn, Ny, Triple Zero Number, Is Kano In Kidulthood,